3,280 Shares in Integer Holdings Co. (NYSE:ITGR) Acquired by EntryPoint Capital LLC

EntryPoint Capital LLC bought a new stake in shares of Integer Holdings Co. (NYSE:ITGR) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 3,280 shares of the medical equipment provider’s stock, valued at approximately $435,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Intech Investment Management LLC acquired a new stake in Integer during the third quarter valued at approximately $1,012,000. Charles Schwab Investment Management Inc. lifted its position in shares of Integer by 1.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 404,029 shares of the medical equipment provider’s stock valued at $52,524,000 after acquiring an additional 4,946 shares during the last quarter. Cerity Partners LLC boosted its stake in shares of Integer by 11.5% during the 3rd quarter. Cerity Partners LLC now owns 32,961 shares of the medical equipment provider’s stock worth $4,285,000 after acquiring an additional 3,389 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Integer by 20,000.0% in the 3rd quarter. Larson Financial Group LLC now owns 1,005 shares of the medical equipment provider’s stock worth $131,000 after acquiring an additional 1,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in shares of Integer by 5.0% during the third quarter. The Manufacturers Life Insurance Company now owns 189,919 shares of the medical equipment provider’s stock worth $24,689,000 after purchasing an additional 9,057 shares during the period. Institutional investors and hedge funds own 99.29% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on ITGR. Wells Fargo & Company restated an “overweight” rating and set a $160.00 price objective on shares of Integer in a report on Tuesday, December 3rd. Citigroup boosted their price target on shares of Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, December 11th. Truist Financial lifted their price objective on shares of Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. KeyCorp increased their target price on Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Finally, Benchmark lifted their price target on Integer from $140.00 to $150.00 and gave the company a “buy” rating in a report on Friday, February 21st. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $149.00.

Integer Stock Up 1.6 %

Shares of ITGR opened at $119.02 on Wednesday. Integer Holdings Co. has a 12 month low of $107.11 and a 12 month high of $146.36. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average price of $131.84 and a two-hundred day moving average price of $132.22. The stock has a market cap of $4.00 billion, a price-to-earnings ratio of 35.42, a P/E/G ratio of 1.72 and a beta of 1.24.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The firm had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. Equities analysts predict that Integer Holdings Co. will post 6.01 EPS for the current fiscal year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.